Bristol-Myers Squibb
Bristol-Myers Squibb is an American biopharmaceutical company engaged in the research, development, manufacture, and delivery of specialized human prescription medicines. The company focuses its research and commercial divisions on core therapeutic areas including oncology, hematology, cardiovascular disease, and immunology. Its biopharmaceutical product lineup features major commercial therapeutics such as Eliquis, Opdivo, Revlimid, Pomalyst, and Yervoy. Revenue is driven by global wholesale distribution of proprietary pharmaceuticals to drug wholesalers, retail pharmacy chains, and medical institutions. Bristol-Myers Squibb maintains a leading global market position in immuno-oncology treatments and oral anticoagulant therapies. The company is headquartered in Princeton, New Jersey, and its common stock is traded on the New York Stock Exchange under ticker symbol BMY.
129 of the funds FundTelligence covers report a position in Bristol-Myers Squibb.
- Legal name
- Bristol-Myers Squibb Co
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 129
Funds holding Bristol-Myers Squibb
- Schroder ISF Global Sustainable Value — Schroders · 3.92 % (full portfolio disclosed, June 2026)
- UBS Sustainable Health Transformation Equity Fund — UBS · 3.8 % (largest positions only, September 2026)
- Fondsfinans Global Helse — Fondsfinans · 3.54 % (full portfolio disclosed, October 2026)
- DWS Invest CROCI Sectors Plus — DWS · 3.28 % (full portfolio disclosed, June 2026)
- JPM Global Healthcare Fund — JPM · 2.92 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI US — DWS · 2.65 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Recovery — Schroders · 2.5 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Dividend Maximiser — Schroders · 2.45 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 129 funds holding it.